Amrubicin Monotherapy for Patients with Platinum-Refractory Gastroenteropancreatic Neuroendocrine Carcinoma
Objective. Patients with gastroenteropancreatic neuroendocrine carcinoma (NEC) have a poor prognosis. Platinum-based combination chemotherapy is commonly used as first-line treatment; however, the role of salvage chemotherapy remains unknown. This study aimed to analyze the efficacy and safety of am...
Saved in:
| Main Authors: | , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2015-01-01
|
| Series: | Gastroenterology Research and Practice |
| Online Access: | http://dx.doi.org/10.1155/2015/425876 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832558211136225280 |
|---|---|
| author | Takayuki Ando Ayumu Hosokawa Hiroki Yoshita Akira Ueda Shinya Kajiura Hiroshi Mihara Sohachi Nanjo Haruka Fujinami Jun Nishikawa Kohei Ogawa Takahiko Nakajima Johji Imura Toshiro Sugiyama |
| author_facet | Takayuki Ando Ayumu Hosokawa Hiroki Yoshita Akira Ueda Shinya Kajiura Hiroshi Mihara Sohachi Nanjo Haruka Fujinami Jun Nishikawa Kohei Ogawa Takahiko Nakajima Johji Imura Toshiro Sugiyama |
| author_sort | Takayuki Ando |
| collection | DOAJ |
| description | Objective. Patients with gastroenteropancreatic neuroendocrine carcinoma (NEC) have a poor prognosis. Platinum-based combination chemotherapy is commonly used as first-line treatment; however, the role of salvage chemotherapy remains unknown. This study aimed to analyze the efficacy and safety of amrubicin monotherapy in patients with platinum-refractory gastroenteropancreatic NEC. Methods. Among 22 patients with advanced gastroenteropancreatic NEC, 10 received amrubicin monotherapy between September 2007 and May 2014 after failure of platinum-based chemotherapy. The efficacy and toxicity of the treatment were analyzed retrospectively. Results. Eight males and two females (median age, 67 years (range, 52–78)) received platinum-based chemotherapy, including cisplatin plus irinotecan (n=7, 70%), cisplatin plus etoposide (n=2, 20%), and carboplatin plus etoposide (n=1, 10%) before amrubicin therapy. Median progression-free survival and overall survival after amrubicin therapy were 2.6 and 5.0 months, respectively. Two patients had partial response (20% response rate), and their PFS were 6.2 months and 6.3 months, respectively. Furthermore, NEC with response for amrubicin had characteristics with a high Ki-67 index and receipt of prior chemotherapy with cisplatin and irinotecan. Grade 3-4 neutropenia and anemia were observed in four and five patients, respectively. Conclusion. Amrubicin monotherapy appears to be potentially active and well-tolerated for platinum-refractory gastroenteropancreatic NEC. |
| format | Article |
| id | doaj-art-e6f1c619389149938aa932d9215fa31e |
| institution | Kabale University |
| issn | 1687-6121 1687-630X |
| language | English |
| publishDate | 2015-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Gastroenterology Research and Practice |
| spelling | doaj-art-e6f1c619389149938aa932d9215fa31e2025-02-03T01:33:05ZengWileyGastroenterology Research and Practice1687-61211687-630X2015-01-01201510.1155/2015/425876425876Amrubicin Monotherapy for Patients with Platinum-Refractory Gastroenteropancreatic Neuroendocrine CarcinomaTakayuki Ando0Ayumu Hosokawa1Hiroki Yoshita2Akira Ueda3Shinya Kajiura4Hiroshi Mihara5Sohachi Nanjo6Haruka Fujinami7Jun Nishikawa8Kohei Ogawa9Takahiko Nakajima10Johji Imura11Toshiro Sugiyama12Department of Gastroenterology and Hematology, Faculty of Medicine, University of Toyama, Sugitani, Toyama 2630, JapanDepartment of Gastroenterology and Hematology, Faculty of Medicine, University of Toyama, Sugitani, Toyama 2630, JapanDepartment of Gastroenterology and Hematology, Faculty of Medicine, University of Toyama, Sugitani, Toyama 2630, JapanDepartment of Gastroenterology and Hematology, Faculty of Medicine, University of Toyama, Sugitani, Toyama 2630, JapanDepartment of Gastroenterology and Hematology, Faculty of Medicine, University of Toyama, Sugitani, Toyama 2630, JapanDepartment of Gastroenterology and Hematology, Faculty of Medicine, University of Toyama, Sugitani, Toyama 2630, JapanDepartment of Gastroenterology and Hematology, Faculty of Medicine, University of Toyama, Sugitani, Toyama 2630, JapanDepartment of Gastroenterology and Hematology, Faculty of Medicine, University of Toyama, Sugitani, Toyama 2630, JapanDepartment of Gastroenterology and Hematology, Faculty of Medicine, University of Toyama, Sugitani, Toyama 2630, JapanDepartment of Gastroenterology and Hematology, Faculty of Medicine, University of Toyama, Sugitani, Toyama 2630, JapanDepartment of Diagnostic Pathology, Graduate School of Medicine and Pharmaceutical Sciences, University of Toyama, Sugitani, Toyama 2630, JapanDepartment of Diagnostic Pathology, Graduate School of Medicine and Pharmaceutical Sciences, University of Toyama, Sugitani, Toyama 2630, JapanDepartment of Gastroenterology and Hematology, Faculty of Medicine, University of Toyama, Sugitani, Toyama 2630, JapanObjective. Patients with gastroenteropancreatic neuroendocrine carcinoma (NEC) have a poor prognosis. Platinum-based combination chemotherapy is commonly used as first-line treatment; however, the role of salvage chemotherapy remains unknown. This study aimed to analyze the efficacy and safety of amrubicin monotherapy in patients with platinum-refractory gastroenteropancreatic NEC. Methods. Among 22 patients with advanced gastroenteropancreatic NEC, 10 received amrubicin monotherapy between September 2007 and May 2014 after failure of platinum-based chemotherapy. The efficacy and toxicity of the treatment were analyzed retrospectively. Results. Eight males and two females (median age, 67 years (range, 52–78)) received platinum-based chemotherapy, including cisplatin plus irinotecan (n=7, 70%), cisplatin plus etoposide (n=2, 20%), and carboplatin plus etoposide (n=1, 10%) before amrubicin therapy. Median progression-free survival and overall survival after amrubicin therapy were 2.6 and 5.0 months, respectively. Two patients had partial response (20% response rate), and their PFS were 6.2 months and 6.3 months, respectively. Furthermore, NEC with response for amrubicin had characteristics with a high Ki-67 index and receipt of prior chemotherapy with cisplatin and irinotecan. Grade 3-4 neutropenia and anemia were observed in four and five patients, respectively. Conclusion. Amrubicin monotherapy appears to be potentially active and well-tolerated for platinum-refractory gastroenteropancreatic NEC.http://dx.doi.org/10.1155/2015/425876 |
| spellingShingle | Takayuki Ando Ayumu Hosokawa Hiroki Yoshita Akira Ueda Shinya Kajiura Hiroshi Mihara Sohachi Nanjo Haruka Fujinami Jun Nishikawa Kohei Ogawa Takahiko Nakajima Johji Imura Toshiro Sugiyama Amrubicin Monotherapy for Patients with Platinum-Refractory Gastroenteropancreatic Neuroendocrine Carcinoma Gastroenterology Research and Practice |
| title | Amrubicin Monotherapy for Patients with Platinum-Refractory Gastroenteropancreatic Neuroendocrine Carcinoma |
| title_full | Amrubicin Monotherapy for Patients with Platinum-Refractory Gastroenteropancreatic Neuroendocrine Carcinoma |
| title_fullStr | Amrubicin Monotherapy for Patients with Platinum-Refractory Gastroenteropancreatic Neuroendocrine Carcinoma |
| title_full_unstemmed | Amrubicin Monotherapy for Patients with Platinum-Refractory Gastroenteropancreatic Neuroendocrine Carcinoma |
| title_short | Amrubicin Monotherapy for Patients with Platinum-Refractory Gastroenteropancreatic Neuroendocrine Carcinoma |
| title_sort | amrubicin monotherapy for patients with platinum refractory gastroenteropancreatic neuroendocrine carcinoma |
| url | http://dx.doi.org/10.1155/2015/425876 |
| work_keys_str_mv | AT takayukiando amrubicinmonotherapyforpatientswithplatinumrefractorygastroenteropancreaticneuroendocrinecarcinoma AT ayumuhosokawa amrubicinmonotherapyforpatientswithplatinumrefractorygastroenteropancreaticneuroendocrinecarcinoma AT hirokiyoshita amrubicinmonotherapyforpatientswithplatinumrefractorygastroenteropancreaticneuroendocrinecarcinoma AT akiraueda amrubicinmonotherapyforpatientswithplatinumrefractorygastroenteropancreaticneuroendocrinecarcinoma AT shinyakajiura amrubicinmonotherapyforpatientswithplatinumrefractorygastroenteropancreaticneuroendocrinecarcinoma AT hiroshimihara amrubicinmonotherapyforpatientswithplatinumrefractorygastroenteropancreaticneuroendocrinecarcinoma AT sohachinanjo amrubicinmonotherapyforpatientswithplatinumrefractorygastroenteropancreaticneuroendocrinecarcinoma AT harukafujinami amrubicinmonotherapyforpatientswithplatinumrefractorygastroenteropancreaticneuroendocrinecarcinoma AT junnishikawa amrubicinmonotherapyforpatientswithplatinumrefractorygastroenteropancreaticneuroendocrinecarcinoma AT koheiogawa amrubicinmonotherapyforpatientswithplatinumrefractorygastroenteropancreaticneuroendocrinecarcinoma AT takahikonakajima amrubicinmonotherapyforpatientswithplatinumrefractorygastroenteropancreaticneuroendocrinecarcinoma AT johjiimura amrubicinmonotherapyforpatientswithplatinumrefractorygastroenteropancreaticneuroendocrinecarcinoma AT toshirosugiyama amrubicinmonotherapyforpatientswithplatinumrefractorygastroenteropancreaticneuroendocrinecarcinoma |